NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Novocure's recent announcement was for Germany, not the EU. They think they might get some kind of reimbursement from Germany for GBM in October 2020 -- if it's any calculation like France and the UK gave, it's fools gold.

Agreed.

The German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published Novocure's (NASDAQ:NVCR) rapid report concluding that, based on a review of its EF-14 phase 3 trial, patients with newly diagnosed glioblastoma (GBM) lived longer when treated with Optune in addition to standard chemotherapy.

This positive conclusion will help Novocure to secure national reimbursement for Optune in Germany.

National reimbursement decision for Optune in Germany anticipated in 2020.

As the review process advances, Novocure will continue to bill payers for individual cases. Each case is evaluated individually on its merits and under the payer’s specific rules for such cases.

https://seekingalpha.com/news/3473851-iqwig-publishes-novocures-optune-report-gbm

https://www.biospace.com/article/releases/german-institute-for-quality-and-efficiency-in-healthcare-publishes-rapid-report-noting-optune-s-survival-benefit-for-patients-with-newly-diagnosed-glioblastoma/

note: i think you are dealing with the "weekend" ex.